ArticleFrontiers in cell and developmental biology2026
The phenotypic heterogeneity of tumor-derived cells in the bloodstream of pancreatic cancer patients.
Article in Frontiers in cell and developmental biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Pancreatic cancer (PC) remains an aggressive malignancy with poor clinical outcomes, underscoring the need for novel biomarkers to monitor patients. Immune checkpoint molecules [programmed death ligand 1 (PD-L1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4)] have been detected in CTCs, and their expression is associated with poor prognosis. Overexpression of STIM1 and ORAI1, core regulators of calcium signaling, and the amino acid transporter chaperone CD98hc, have been shown to enhance cancer cell survival and migration. This study evaluated the expression of these molecules in PC-CTCs, alongside cytokeratin (CK, tumor cell marker) and CD45 (pan leukocyte marker). Methods: CTCs were isolated from 40 patients using Ficoll density gradient centrifugation and characterized by immunofluorescence. Additionally, 15 were analyzed using the ISET platform. PBMCs from 10 healthy donors were also evaluated. Biomarker expression was assessed using the automated VyCAP platform, followed by ACCEPT software evaluation and statistical analysis of adjunct clinical data. Results: CTCs were detected in 20% of patients, whereas all displayed (CK-/CD45-) cells with tumor characteristics and nucleus size of ≥10 μm, designated as circulating tumor-associated cells (CTACs). CTACs were significantly elevated in patients compared to healthy donors, and ROC analysis demonstrated strong discriminative capacity (AUC = 0.9083). Similarly, using the ISET platform, CTCs were detected in 26.7% (4/15), whereas CTACs were detected in 93.3% (14/15). PD-L1-positive CTCs were identified in 2.5% of patients, while PD-L1 and CTLA-4 expression on CTACs was detected in 30% and 17.5% of patients, respectively. STIM1-positive and ORAI1-positive CTCs were observed in 15% and 2.5% of patients, while expression on CTACs was detected in 70% and 10% of patients. Concerning CD98hc, 32.5% of patients harbored (CD98hc+/CD45-) cells. Interestingly, metastatic patients with PD-L1-positive CTCs exhibited shorter overall survival (OS; Discussion: These findings provide a comprehensive characterization of CTCs and CTACs in PC using a multiplex biomarker panel associated with calcium signaling and immune checkpoint pathways, highlighting the pronounced heterogeneity and potential clinical relevance of these circulating cell populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.